Immunology · Year 2 · from Immunology
Case 1: Severe COVID-19 with Cytokine Storm
Clinical Image
Source: Wikipedia - Cytokine storm - CC BY-SA 4.0
Case Presentation
A 58-year-old male with type 2 diabetes mellitus (HbA1c 8.9%) and obesity (BMI 34) presents to the emergency department with 8 days of progressive dyspnea, dry cough, and fever up to 39.8C. He tested positive for SARS-CoV-2 by rapid antigen 6 days ago and initially managed symptoms at home with acetaminophen. Over the past 48 hours, he developed worsening hypoxia requiring supplemental oxygen. On examination, he is tachypneic (RR 32/min), tachycardic (HR 118 bpm), febrile (39.4C), and hypoxic (SpO2 82% on room air). Bilateral crackles are auscultated to the mid-lung fields. Chest CT reveals diffuse bilateral ground-glass opacities with areas of consolidation. Laboratory studies reveal markedly elevated IL-6 (342 pg/mL; normal <7), ferritin (2,840 ng/mL), CRP (218 mg/L), D-dimer (4.2 mcg/mL FEU), LDH (612 U/L), and lymphopenia (absolute lymphocyte count 0.4 x 10^9/L). Troponin I is mildly elevated at 0.08 ng/mL. He is admitted to the ICU, initiated on high-flow nasal cannula at 60 L/min with FiO2 0.90, dexamethasone 6 mg IV daily, and tocilizumab 8 mg/kg IV for refractory hyperinflammation. Remdesivir 200 mg IV loading dose followed by 100 mg daily is started. Despite intervention, he requires intubation on hospital day 3 with P/F ratio of 88, consistent with severe ARDS.
Key Learning Points
- Delayed type I interferon (IFN-alpha/beta) responses in severe COVID-19 permit unchecked viral replication during the first week, leading to a compensatory hyperinflammatory cascade characterized by excessive IL-6, TNF-alpha, and IL-1beta release from activated macrophages and monocytes
- Cytokine storm in COVID-19 is driven by a maladaptive innate immune response: impaired plasmacytoid dendritic cell IFN production combined with inflammasome activation (NLRP3) and pyroptosis of infected cells amplifies systemic inflammation
- Lymphopenia (particularly CD4+ and CD8+ T cell depletion) is a hallmark of severe disease and correlates with impaired viral clearance, creating a vicious cycle of viral persistence and immune hyperactivation
- Dexamethasone reduces 28-day mortality in patients requiring supplemental oxygen (RECOVERY trial), while tocilizumab (anti-IL-6 receptor) provides additional benefit in patients with rapidly escalating oxygen requirements and elevated inflammatory markers